Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127501091 | 12750109 | 1 | I | 20160823 | 20160916 | 20160916 | EXP | US-ROCHE-1829933 | ROCHE | 62.00 | YR | F | Y | 72.40000 | KG | 20160916 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127501091 | 12750109 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1460 | MG | ||||||||
| 127501091 | 12750109 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1420 | MG | ||||||||
| 127501091 | 12750109 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1328 | MG | ||||||||
| 127501091 | 12750109 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1110 | MG | ||||||||
| 127501091 | 12750109 | 5 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1064 | MG | ||||||||
| 127501091 | 12750109 | 6 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1032 | MG | ||||||||
| 127501091 | 12750109 | 7 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 960 | MG | ||||||||
| 127501091 | 12750109 | 8 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 974 | MG | ||||||||
| 127501091 | 12750109 | 9 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1066 | MG | ||||||||
| 127501091 | 12750109 | 10 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 1004 | MG | ||||||||
| 127501091 | 12750109 | 11 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125085 | 520 | MG | ||||||||
| 127501091 | 12750109 | 12 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 100 | MG | ||||||||
| 127501091 | 12750109 | 13 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 100 | MG | ||||||||
| 127501091 | 12750109 | 14 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 100 | MG | ||||||||
| 127501091 | 12750109 | 15 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 100 | MG | ||||||||
| 127501091 | 12750109 | 16 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 100 | MG | ||||||||
| 127501091 | 12750109 | 17 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 100 | MG | ||||||||
| 127501091 | 12750109 | 18 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 80 | MG | ||||||||
| 127501091 | 12750109 | 19 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 80 | MG | ||||||||
| 127501091 | 12750109 | 20 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 80 | MG | ||||||||
| 127501091 | 12750109 | 21 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 80 | MG | ||||||||
| 127501091 | 12750109 | 22 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | U | 0 | 40 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127501091 | 12750109 | 1 | Endometrial cancer |
| 127501091 | 12750109 | 12 | Endometrial cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127501091 | 12750109 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127501091 | 12750109 | Hypokalaemia | |
| 127501091 | 12750109 | Pericardial effusion | |
| 127501091 | 12750109 | Proteinuria |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127501091 | 12750109 | 1 | 20100601 | 0 | ||
| 127501091 | 12750109 | 2 | 20100628 | 0 | ||
| 127501091 | 12750109 | 3 | 20100920 | 0 | ||
| 127501091 | 12750109 | 4 | 20110207 | 0 | ||
| 127501091 | 12750109 | 5 | 20110627 | 0 | ||
| 127501091 | 12750109 | 6 | 20120306 | 0 | ||
| 127501091 | 12750109 | 7 | 20120402 | 0 | ||
| 127501091 | 12750109 | 8 | 20120430 | 0 | ||
| 127501091 | 12750109 | 9 | 20120604 | 0 | ||
| 127501091 | 12750109 | 10 | 20121022 | 0 | ||
| 127501091 | 12750109 | 11 | 20121119 | 0 | ||
| 127501091 | 12750109 | 12 | 20100601 | 0 | ||
| 127501091 | 12750109 | 13 | 20100628 | 0 | ||
| 127501091 | 12750109 | 14 | 20100920 | 0 | ||
| 127501091 | 12750109 | 15 | 20110207 | 0 | ||
| 127501091 | 12750109 | 16 | 20110627 | 0 | ||
| 127501091 | 12750109 | 17 | 20120306 | 0 | ||
| 127501091 | 12750109 | 18 | 20120402 | 0 | ||
| 127501091 | 12750109 | 19 | 20120430 | 0 | ||
| 127501091 | 12750109 | 20 | 20120604 | 0 | ||
| 127501091 | 12750109 | 21 | 20121022 | 0 | ||
| 127501091 | 12750109 | 22 | 20121119 | 0 |